Skip to main content

Table 2 Characteristics of patients treated with talimogene laherparepvec in OPTiM by complete response and partial response (per investigator assessment)a

From: Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

Characteristic Complete response (n = 50) Partial response (n = 43)
Median (IQR) age, years 70 (60–78) 63 (53–77)
Female 20 (40) 21 (49)
ECOG performance status = 0 42 (84) 31 (72)
AJCC stage
 IIIB/C 31 (62) 15 (35)
 IVM1a 15 (30) 14 (33)
 IIIB–IVM1a 46 (92) 29 (67)
 IVM1b 2 (4) 7 (16)
 IVM1c 2 (4) 7 (16)
In-transit or distant skin metastases
 IIIB–IVM1a 42 (84) 20 (47)
 IIIB–IVM1c 44 (88) 26 (60)
Elevated LDH (>ULN) 0 0
Line of treatment
 1st 33 (66) 27 (63)
  ≥ 2nd 17 (34) 16 (37)
Median baseline tumor burden (range), cm2 4.6 (0.3–38.3) 10.9 (0.6–280.6)
BRAF status
 Mutation 5 (10) 9 (21)
 Wild type 5 (10) 9 (21)
 Unknown/missing 40 (80) 25 (58)
HSV-1 seropositive at baseline 32 (64) 28 (65)
  1. Data presented are number (%) of patients, unless otherwise indicated
  2. aAmong 295 patients randomized to talimogene laherparepvec, 291 received treatment and 287 were evaluable for response assessment per investigator assessment
  3. AJCC American Joint Committee on Cancer, ECOG Eastern Cooperative Oncology Group, HSV herpes simplex virus, IQR interquartile range, LDH lactate dehydrogenase, ULN upper limit of normal